BioCentury | Jan 25, 2021
Finance

TScan to bring five T cell therapies to the clinic by 2022 with $100M series C

With a $100 million series C round from a deep-pocketed syndicate that includes BlackRock and RA Capital, T cell therapy developer TScan is aiming to bring five programs into the clinic by 2022.  TScan Therapeutics...
BioCentury | Mar 12, 2020
Product Development

Targeted degradation gets another bump with Kymera’s $102M raise

It’s a big year for targeted protein degraders, and Kymera is adding to the momentum with a $102 million series C round that should bring its first three programs into the clinic. Biotechnology Value Fund...
BioCentury | Aug 17, 2018
Financial News

Crossover investors join Orchard's syndicate in $150M series C

Gene therapy company Orchard Therapeutics Ltd. (London, U.K.) raised $150 million on Aug. 13 in a series C round led by Deerfield Management. Also participating were new investors RA Capital, Venrock, Foresite Capital, Perceptive Advisors,...
BioCentury | Aug 13, 2018
Financial News

Crossover investors join Orchard's syndicate in $150M series C

Gene therapy company Orchard Therapeutics Ltd. (London, U.K.) raised $150 million in a series C round led by Deerfield Management. Also participating were new investors RA Capital, Venrock, Foresite Capital, Perceptive Advisors, Cormorant Asset Management,...
BioCentury | Nov 5, 2015
Financial News

Atreca raises $56M in series A

Atreca Inc. (Redwood City, Calif.) closed a $56 million series A round led by an undisclosed U.S. healthcare-focused fund. The Bill & Melinda Gates Foundation , Mission Bay Capital and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) also participated....
BioCentury | Aug 11, 2014
Financial News

Juno Therapeutics completes venture financing

Juno Therapeutics Inc. , Seattle, Wash. Business: Cancer Date completed: 2014-08-05 Type: Venture financing Raised: $134 million Investors: New investors; existing investors Note: The round included 10 undisclosed, new public mutual funds and healthcare-focused funds. The...
BioCentury | Aug 6, 2014
Top Story

Juno raises $134 million in B round

Cancer immunotherapy company Juno Therapeutics Inc. (Seattle, Wash.) raised $134 million in a series B round from 10 undisclosed, new public mutual funds and healthcare-focused funds. The company said all of its "major" existing investors...
BioCentury | Oct 14, 2013
Finance

Cornering Ventures West

Cornering Ventures West After 40 years, Ventures West decided to close up shop this month rather than raise another multi-sector fund. Two life science specialists - one current and one former partner - will manage the firm's...
BioCentury | Oct 18, 2012
Financial News

Nodelman leaves BVF to launch new healthcare fund

Oleg Nodelman, a portfolio manager at BVF Partners, said in a statement he is leaving the firm to launch his own healthcare-focused fund -- EcoR1 Capital. Nodelman, who is a non-executive director at Swiss neurology...
BioCentury | Oct 3, 2011
Finance

Cost averaging down

Even the best fundamentals may not be able to overcome the negative effects of the broader economy on the stock market this quarter. As a result, specialists have little hope of major gains and instead...
Items per page:
1 - 10 of 12
BioCentury | Jan 25, 2021
Finance

TScan to bring five T cell therapies to the clinic by 2022 with $100M series C

With a $100 million series C round from a deep-pocketed syndicate that includes BlackRock and RA Capital, T cell therapy developer TScan is aiming to bring five programs into the clinic by 2022.  TScan Therapeutics...
BioCentury | Mar 12, 2020
Product Development

Targeted degradation gets another bump with Kymera’s $102M raise

It’s a big year for targeted protein degraders, and Kymera is adding to the momentum with a $102 million series C round that should bring its first three programs into the clinic. Biotechnology Value Fund...
BioCentury | Aug 17, 2018
Financial News

Crossover investors join Orchard's syndicate in $150M series C

Gene therapy company Orchard Therapeutics Ltd. (London, U.K.) raised $150 million on Aug. 13 in a series C round led by Deerfield Management. Also participating were new investors RA Capital, Venrock, Foresite Capital, Perceptive Advisors,...
BioCentury | Aug 13, 2018
Financial News

Crossover investors join Orchard's syndicate in $150M series C

Gene therapy company Orchard Therapeutics Ltd. (London, U.K.) raised $150 million in a series C round led by Deerfield Management. Also participating were new investors RA Capital, Venrock, Foresite Capital, Perceptive Advisors, Cormorant Asset Management,...
BioCentury | Nov 5, 2015
Financial News

Atreca raises $56M in series A

Atreca Inc. (Redwood City, Calif.) closed a $56 million series A round led by an undisclosed U.S. healthcare-focused fund. The Bill & Melinda Gates Foundation , Mission Bay Capital and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) also participated....
BioCentury | Aug 11, 2014
Financial News

Juno Therapeutics completes venture financing

Juno Therapeutics Inc. , Seattle, Wash. Business: Cancer Date completed: 2014-08-05 Type: Venture financing Raised: $134 million Investors: New investors; existing investors Note: The round included 10 undisclosed, new public mutual funds and healthcare-focused funds. The...
BioCentury | Aug 6, 2014
Top Story

Juno raises $134 million in B round

Cancer immunotherapy company Juno Therapeutics Inc. (Seattle, Wash.) raised $134 million in a series B round from 10 undisclosed, new public mutual funds and healthcare-focused funds. The company said all of its "major" existing investors...
BioCentury | Oct 14, 2013
Finance

Cornering Ventures West

Cornering Ventures West After 40 years, Ventures West decided to close up shop this month rather than raise another multi-sector fund. Two life science specialists - one current and one former partner - will manage the firm's...
BioCentury | Oct 18, 2012
Financial News

Nodelman leaves BVF to launch new healthcare fund

Oleg Nodelman, a portfolio manager at BVF Partners, said in a statement he is leaving the firm to launch his own healthcare-focused fund -- EcoR1 Capital. Nodelman, who is a non-executive director at Swiss neurology...
BioCentury | Oct 3, 2011
Finance

Cost averaging down

Even the best fundamentals may not be able to overcome the negative effects of the broader economy on the stock market this quarter. As a result, specialists have little hope of major gains and instead...
Items per page:
1 - 10 of 12